Blueprint Medicines Dirección
Dirección controles de criterios 3/4
El CEO de Blueprint Medicines es Kate Haviland , nombrado en Apr 2022, tiene una permanencia de 2.58 años. compensación anual total es $6.43M, compuesta por 12.2% salario y 87.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.094% de las acciones de la empresa, por valor de $5.62M. La antigüedad media del equipo directivo y de la junta directiva es de 4.2 años y 9.5 años, respectivamente.
Información clave
Kate Haviland
Chief Executive Officer (CEO)
US$6.4m
Compensación total
| Porcentaje del salario del CEO | 12.2% |
| Permanencia del CEO | 2.6yrs |
| Participación del CEO | 0.09% |
| Permanencia media de la dirección | 4.2yrs |
| Promedio de permanencia en la Junta Directiva | 9.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Nov 24
Blueprint Medicines: Growth For The Long Term Still Mostly Priced In
Sep 27Is Blueprint Medicines (NASDAQ:BPMC) Using Too Much Debt?
Aug 16Some Confidence Is Lacking In Blueprint Medicines Corporation's (NASDAQ:BPMC) P/S
Jul 23Blueprint Medicines: Overdue For A Breather
Jul 16Blueprint Medicines Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
May 05Blueprint Medicines: Rampant Growth Mostly Priced In
May 04Is Blueprint Medicines (NASDAQ:BPMC) Using Debt In A Risky Way?
Apr 26Risks To Shareholder Returns Are Elevated At These Prices For Blueprint Medicines Corporation (NASDAQ:BPMC)
Apr 05Blueprint Medicines: Ayvakit Revenue Surge Fuels Optimism (Rating Upgrade)
Feb 20Blueprint Medicines Corporation (NASDAQ:BPMC) Shares Could Be 29% Below Their Intrinsic Value Estimate
Jan 08Subdued Growth No Barrier To Blueprint Medicines Corporation (NASDAQ:BPMC) With Shares Advancing 38%
Dec 18Is Blueprint Medicines (NASDAQ:BPMC) Weighed On By Its Debt Load?
Nov 20Is Blueprint Medicines (NASDAQ:BPMC) Using Debt Sensibly?
Jul 26Health Check: How Prudently Does Blueprint Medicines (NASDAQ:BPMC) Use Debt?
Apr 16Is Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 09Despite Lacking Profits Blueprint Medicines (NASDAQ:BPMC) Seems To Be On Top Of Its Debt
Dec 12Need To Know: Analysts Just Made A Substantial Cut To Their Blueprint Medicines Corporation (NASDAQ:BPMC) Estimates
Nov 07Blueprint Medicines: Royalties Being Sold Allows For More Shots On Goal
Sep 15Blueprint to seek label expansion for systemic mastocytosis therapy after trial win
Aug 17Blueprint Medicines reports Q2 earnings miss; reaffirms FY22 guidance
Aug 02Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$128m |
| Jun 30 2024 | n/a | n/a | -US$205m |
| Mar 31 2024 | n/a | n/a | -US$288m |
| Dec 31 2023 | US$6m | US$782k | -US$507m |
| Sep 30 2023 | n/a | n/a | -US$555m |
| Jun 30 2023 | n/a | n/a | -US$554m |
| Mar 31 2023 | n/a | n/a | -US$581m |
| Dec 31 2022 | US$6m | US$701k | -US$558m |
| Sep 30 2022 | n/a | n/a | -US$718m |
| Jun 30 2022 | n/a | n/a | -US$702m |
| Mar 31 2022 | n/a | n/a | -US$650m |
| Dec 31 2021 | US$4m | US$501k | -US$644m |
| Sep 30 2021 | n/a | n/a | -US$411m |
| Jun 30 2021 | n/a | n/a | US$340m |
| Mar 31 2021 | n/a | n/a | US$325m |
| Dec 31 2020 | US$2m | US$461k | US$314m |
| Sep 30 2020 | n/a | n/a | US$333m |
| Jun 30 2020 | n/a | n/a | -US$395m |
| Mar 31 2020 | n/a | n/a | -US$371m |
| Dec 31 2019 | US$3m | US$432k | -US$348m |
| Sep 30 2019 | n/a | n/a | -US$362m |
| Jun 30 2019 | n/a | n/a | -US$340m |
| Mar 31 2019 | n/a | n/a | -US$267m |
| Dec 31 2018 | US$3m | US$393k | -US$237m |
| Sep 30 2018 | n/a | n/a | -US$205m |
| Jun 30 2018 | n/a | n/a | -US$170m |
| Mar 31 2018 | n/a | n/a | -US$177m |
| Dec 31 2017 | US$1m | US$353k | -US$148m |
Compensación vs. Mercado: La compensación total ($USD6.43M) de Kate está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD7.78M).
Compensación vs. Ingresos: La compensación de Kate ha aumentado mientras la empresa no es rentable.
CEO
Kate Haviland (48 yo)
2.6yrs
Permanencia
US$6,432,012
Compensación
Ms. Kathryn Haviland, also known as Kate, M.B.A, is Independent Director of Bicara Therapeutic, Inc. from September 2023. She has been a Director of Fulcrum Therapeutics, Inc. since June 27, 2018. She serv...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.6yrs | US$6.43m | 0.094% $ 5.6m | |
| Co-Founder & Director | no data | US$397.33k | 0.11% $ 6.8m | |
| Chief Financial Officer | 8.8yrs | US$2.19m | 0.056% $ 3.4m | |
| Chief Operating Officer | 2.6yrs | US$2.81m | 0.043% $ 2.6m | |
| Chief Scientific Officer | 3.5yrs | US$2.30m | 0.078% $ 4.6m | |
| President of Research & Development | 4.2yrs | US$2.80m | 0.050% $ 3.0m | |
| Senior VP | 1.8yrs | sin datos | 0.023% $ 1.4m | |
| Senior Director & Head of Investor Relations | no data | sin datos | sin datos | |
| Executive VP | 8.2yrs | US$2.34m | 0.046% $ 2.7m | |
| Chief People Officer | 4.8yrs | sin datos | 0.019% $ 1.2m | |
| Senior Vice President of Corporate Affairs | no data | sin datos | sin datos | |
| Chief Medical Officer | 4.5yrs | sin datos | 0.046% $ 2.8m |
4.2yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BPMC se considera experimentado (4.2 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 2.6yrs | US$6.43m | 0.094% $ 5.6m | |
| Co-Founder & Director | 13.6yrs | US$397.33k | 0.11% $ 6.8m | |
| Chair of Scientific Advisory Board | 12.5yrs | US$333.38k | sin datos | |
| Lead Independent Director | 8.6yrs | US$452.33k | 0.017% $ 1.0m | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board & Independent Director | 13.6yrs | US$417.33k | 0.088% $ 5.2m | |
| Independent Director | 8.8yrs | US$419.33k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 2.9yrs | US$422.33k | 0.014% $ 807.4k | |
| Chairman | 10.3yrs | US$526.08k | 0.24% $ 14.6m |
9.5yrs
Permanencia media
62yo
Promedio de edad
Junta con experiencia: La junta directiva de BPMC se considera experimentada (9.5 años de antigüedad promedio).